Market Signal Briefing

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

CME Group has confirmed through its official communications on X that spot-quoted futures for XRP and Solana will go live on December 15, subject to regulatory approval. 

The message was simple but clear, and these crypto heavyweights might see new institutional products hitting the market soon. The announcement quickly led to attention across the crypto market, given CME’s position as the leading venue for institutional-grade derivatives.

Understanding Spot-Quoted Futures For XRP And Solana
The crypto market is beginning to regain some upward momentum after several weeks of persistent declines. Prices have struggled since the start of November, yet the industry has continued moving forward in important areas. 

This trend is especially due to the launch of Spot XRP ETFs and Spot Solana ETFs in the US, with issuers like VanEck, Bitwise, Fidelity, and Franklin Templeton all introducing altcoin-based products that are now competing for institutional attention.

The recent update by the CME Group shows that there are still many important crypto products to be launched. The introduction of XRP and Solana into CME’s expanding list of futures offerings arrives at a time when demand from professional investors is widening beyond Bitcoin and Ethereum. 

Institutions have been searching for regulated pathways to participate in major altcoins, and CME’s timeline suggests that both crypto assets are about to enter into a new layer of market infrastructure comparable to Bitcoin and Ethereum.

Spot-quoted futures are designed to follow the live prices seen in the spot market rather than using an index or blended reference rate. CME has structured these contracts to be smaller and easier to access, with the group noting that “good things come in small packages.”

Why This Launch Matters For Institutional Access
CME’s move demonstrates that institutional interest in altcoins has reached a new level. Providing spot-quoted contracts creates a simpler, more direct way for large investors to trade these assets without confronting the operational risks of holding them outright.

CME also disclosed earlier in the year that it plans to introduce full 24/7 trading by early 2026. This step was aimed at matching the continuous pace of the crypto market, rather than waiting for traditional market windows.

In terms of price action, both cryptocurrencies are starting to look good. XRP is now back trading above $2.20, while Solana has reclaimed $140. 

It’s important to note that the new Spot-Quoted XRP and SOL futures are still waiting for approval. As December 15 approaches, many altcoin traders will be watching for regulatory clearance. Once approved, XRP and Solana could experience a noticeable change in institutional interaction, and this will undoubtedly contribute positively to price action before the end of the year.

XRP trading at $2.18 on the 1D chart | Source: XRPUSDT on Tradingview.com
Featured image from Peakpx, chart from Tradingview.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Sign Up for Our Newsletter!
For updates and exclusive offers enter your email.

Scott Matherson is a leading crypto writer at Bitcoinist, who possesses a sharp analytical mind and a deep understanding of the digital currency landscape. Scott has earned a reputation for delivering thought-provoking and well-researched articles that resonate with both newcomers and seasoned crypto enthusiasts.
Outside of his writing, Scott is passionate about promoting crypto literacy and often works to educate the public on the potential of blockchain.

// Price

Reading time: 2 min

Published: Nov 26, 2025 at 17:02

Sui's (SUI) price has fallen below the moving average lines as it approaches its lowest price level.

Sui price long-term prediction: bearish

Currently, SUI has declined and is holding above $1.30. The cryptocurrency price dropped to $1.31 after breaking the previous support level. The price is now correcting upwards to retest its former support, which has become resistance at $1.70.

On the upside, SUI will resume its bullish trend if it retests and breaks above $1.70. The altcoin will then continue its range-bound movement between the $1.70 support and the $4.50 resistance level. However, a rejection at $1.70 will worsen the decline. The bearish momentum is likely to eventually reach the lowest price of $0.46. SUI price is currently at $1.55.

Technical indicators

Key supply zones: $4.00, $4.20, $4.40

Key demand zones: $3.00, $2.80, $2.60  

Sui price indicator analysis

The 21-day SMA and 50-day SMA are trending downwards, with price bars below the 21-day SMA. The current decline will end if the bulls surpass the 21-day SMA and sustain their bullish momentum. On the 4-hour chart, the price bars are above the downward-sloping moving average line. The altcoin will attempt to rise while it remains above the moving average lines.

What is the next move for Sui?

SUI has remained above the $1.30 support level on the 4-hour chart since the price decline on 21 November. The altcoin corrected upwards and became stuck at the $1.60 high. If the cryptocurrency breaks through the $1.60 barrier, it will continue to rise. Otherwise, selling pressure will persist as the altcoin falls from its recent peak and breaks through the present support at $1.30.

Disclaimer. This analysis and forecast are the personal opinions of the author. The data provided is collected by the author and is not sponsored by any company or token developer. This is not a recommendation to buy or sell cryptocurrency and should not be viewed as an endorsement by Coinidol.com. Readers should do their research before investing in funds.

Just a year after developers — led in part by Vitalik Buterin's push for scaling — began advocating for higher gas limits, Ethereum is now operating with a 60 million block gas limit, doubling network capacity in only 12 months.

TL;DR

Grayscale has filed with the SEC to convert its Zcash Trust into the first-ever spot ZEC ETF in the United States.
The ETF aims to provide institutional and retail investors with direct exposure to Zcash while leveraging regulated custodial and brokerage infrastructure.
ZEC has recently experienced a significant price recovery, surging over 1,000% in three months, reflecting renewed investor interest in privacy-focused cryptocurrencies.

Cryptocurrency asset manager Grayscale has submitted an S-3 registration statement to the U.S. Securities and Exchange Commission to launch the first-ever spot Zcash (ZEC) ETF in the United States. The move positions Grayscale to offer a regulated and accessible way for investors to gain exposure to ZEC, a privacy-focused cryptocurrency that has recently regained significant market momentum and is attracting attention from a broader range of institutional and retail participants.

Regulatory Framework And ETF Mechanics
According to the filing, the ETF would be listed on NYSE Arca under the ticker ZCSH. Coinbase Custody will serve as custodian, Coinbase as prime broker, and the Bank of New York Mellon as transfer agent and administrator. Grayscale’s Zcash Trust currently holds approximately 394,400 ZEC, valued at around $199.2 million at current prices. The company emphasizes Zcash’s privacy-preserving features, including shielded transactions enabled by zk-SNARKs, as a key factor in its suitability for a diversified digital asset portfolio and its potential to attract new types of investors seeking regulated exposure.

The SEC approval process for converting trusts into spot ETFs can vary widely. Previous conversions, such as Grayscale’s Dogecoin Trust, took roughly three months, while other multi-crypto ETFs have required closer to a year. Timing will depend on regulatory review and market conditions, with approval paving the way for institutional and retail investors to access ZEC via a familiar exchange-traded product and potentially boosting overall market liquidity.

Zcash Rally Drives Institutional Interest
ZEC has experienced a substantial surge since late September, rising more than 1,000% over three months. This recovery follows a period of regulatory-driven delistings in 2023 and 2024 that had suppressed the token’s liquidity and trading activity. The recent market momentum coincides with the launch of Cypherpunk, a U.S. public digital asset treasury targeting 5% of total Zcash supply, highlighting growing institutional interest in privacy-centric cryptocurrencies. Analysts also note that increased trading volumes across major exchanges are reinforcing ZEC’s market relevance and investor confidence.

The approval of a ZEC ETF could enhance liquidity, broaden market access, and reinforce Zcash’s position as a leading privacy-focused digital asset.  

S&P Global Ratings downgraded Tether's USDT stablecoin to its weakest score due to increased exposure to risky assets and reserve disclosure gaps. The report highlighted concerns over USDT's backing, noting that bitcoin now accounts for 5.6% of its reserves and the chance of lower prices potentially leading to USDT being undercollateralized.

Tether received a 'weak' grade on USDT, as S&P Ratings Global expressed doubts the company had reliable collaterals to support the stablecoin's dollar peg.

Tether's growing footprint in the global gold market has entered the chat in a big way, thanks to a new analysis from Jefferies that frames the stablecoin giant as something akin to a private-sector central bank.

flash news

Hyperliquid Whale Who Netted $200M Now Bets $44.5M on Ethereum

An anonymous whale on the derivatives platform Hyperliquid expanded a major $44.5M long position on Ethereum (ETH) yesterday, according to Arkham Intelligence. The trader reportedly

flash news

Ethereum Giant BitMine Invests $200M, Addresses Market Concerns Over ETH Drop

BitMine Immersion Technologies increased its Ethereum holdings by purchasing 69,822 ETH, bringing its total position to 3,629,701 tokens, equivalent to 3% of the supply. The

CryptoCurrency News

Digital Asset Funds Bleed $1.94B in Outflows — Bitcoin and Ethereum at the Forefront

TL;DR Digital asset funds reported $1.94 billion in weekly outflows, extending a four-week streak totaling $4.92 billion. Bitcoin and Ethereum accounted for the largest withdrawals,

Ethereum News

Bitmine-Linked Wallet Accumulates ETH as BMNR Shares Continue to Fall

TL;DR Bitmine significantly increases its Ethereum holdings during price declines. The company’s shares have fallen over 80% from their July peak. Bitmine is heavily investing

Ethereum News

BitMine Shares Sink Post‑Earnings as Ethereum Drops and Treasury Buzz Fades

TL;DR BitMine reported $328 million in full-year income while announcing its first dividend of one cent per share. Its stock has fallen 52% over the

Ethereum News

Ethereum Hit by Triple Shock: Binance Outflows, Liquidations, and Support Loss Collide

TL;DR Ethereum encounters significant downward pressure as three major market forces converge. Binance ETH outflows, mass liquidations, and a break of the $2800 support level

TLDR:

Table of Contents

TLDR:Upexi Private Placement Targets $23 Million for Solana StrategyFunding Structure Builds on Upexi’s Existing Solana PositionGet 3 Free Stock Ebooks

Upexi seeks up to $23 million to expand its Solana treasury and support corporate operations.
The raise includes $10 million upfront and up to $13 million from warrant exercises at $4.00.
Pricing at $3.04 sits above the company’s at-the-market value under Nasdaq rules.
Upexi plans to file an SEC resale registration within five days of the deal closing.

Upexi has launched a new private placement to raise fresh capital for its Solana treasury strategy. 

The company is targeting up to $23 million through a mix of common stock and warrants. It expects to secure $10 million upfront and the remaining $13 million from warrant exercises. The plan follows steady growth in its Solana holdings and rising demand for institutional crypto treasuries.

Upexi Private Placement Targets $23 Million for Solana Strategy
According to SolanaFloor, Upexi currently holds more than 2 million SOL, positioning it among the largest Solana-focused corporate treasuries. 

The company intends to use the new capital to expand that position while supporting operational needs. Its securities purchase agreement includes 3,289,474 shares and the same number of warrants priced at $3.04 per unit.

Upexi stated in its release that the offering price sits above its at-the-market level under Nasdaq rules. The warrants carry a $4.00 exercise price and remain valid for 48 months. The company said it expects the initial closing to occur around December 1, pending final conditions.

SolanaFloor emphasized the scale of Upexi’s crypto exposure as the raise was announced. The firm’s holdings have been part of a multi-year strategy aligned with the broader Solana market. Upexi plans to channel proceeds into what it calls a maximum return Solana strategy that it manages internally.

The company also addressed its registration commitments following the private placement. It plans to file a resale registration statement within five days of closing. The filing will cover both the new common stock and shares tied to the warrants.

Funding Structure Builds on Upexi’s Existing Solana Position
The deal brings one institutional investor into the round, according to the announcement. 

A.G.P./Alliance Global Partners is acting as the placement agent. Upexi expects net proceeds after fees to go toward working capital and general corporate requirements alongside its Solana program.

The company highlighted that the $3.04 pricing reflects a premium to its fully loaded NAV calculation. That premium aligns with the company’s view of its Solana exposure per share. The structure is designed to be accretive at the treasury level if warrant exercises reach the full $13 million.

The statement also outlined the regulatory terms of the offering. The securities remain unregistered at issuance and fall under private placement exemptions. Any public sale will require the SEC to declare the registration statement effective.

SolanaFloor’s update noted growing interest in Solana-centric corporate treasury models. Upexi has leaned into that trend through consistent accumulation and an emphasis on regulated equity offerings. Its latest move builds on that path with one of its largest raises to date.

After the massive price recovery witnessed a few days ago, XRP has slowed down on its price surge since the last day, but its network has continued to see growing engagements as investors stay resilient on the leading altcoin.

On Wednesday, November 22, onchain analytics firm CryptoQuant disclosed a decent increase in the XRP burn rate despite the plummeting market condition.

XRP network usage growsWhile the network has not witnessed a significant increase yet, the data shows that a decent 521 XRP were destroyed in fees in the last 24 hours. This represents a mild 0.77% surge from the burns achieved yesterday.

HOT Stories

Despite the surge, the number of XRP burned as fees is still relatively low compared to levels seen before the massive October 10 crash that has led the market into persisting price corrections.

Although small but positive, the metric has contributed to the restoration of confidence in the XRP ecosystem as it has come when XRP is seeing fresh momentum following the recent resurgence in its price, alongside the major launches of multiple ETFs.

You Might Also Like

Although XRP has slowed down on its price surge today, the market is still showing signs of a potential rally, suggesting increased demand among retail and institutional investors.

Apparently, the increase in XRP’s burn rate, coinciding with renewed bullish sentiment, has fueled speculation that XRP may be entering a new phase, stirring anticipation for a massive rally in December.

XRP ETFs outperform market While XRP has also joined Bitcoin, Ethereum, and Solana on Wall Street following the recent launch of multiple XRP ETFs, the altcoin is moving to become the next big thing in the crypto ecosystem.

Notably, the launch of these ETFs has made XRP the center of attention, with market watchers predicting that the impressive inflows pulled by these ETFs in just a few days of launch could position XRP back to its $5 target for 2025.

Just yesterday, ETF trackers reported that XRP flipped Bitcoin, Ethereum, and Solana in daily ETF inflow. XRP ETFs recorded a massive $164 million in inflows as of November 25, while Bitcoin, Ethereum, and Solana pulled in $151 million, $97 million, and $58 million respectively.

RGTI's sharp stock gains and improved earnings outlook rival IONQ's stronger balance sheet and revenue surge heading into 2026.

About Emily Jarvie
Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The Canberra Times, and... Read more

About the publisher
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists.

Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth.

We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors.

The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies.

Use of technology
Proactive has always been a forward looking and enthusiastic technology adopter.

Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows.

Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation.

Nvidia ‘s (NASDAQ:NVDA) evolution from a gaming chips maker to the premier supplier for AI systems has been nothing short of astounding.

SummaryAlphabet Inc. built a structural edge through TPUs and end-to-end AI integration, cutting costs and widening margins across the AI cycle. has emerged as a leader in AI, driven by Gemini 3 and proprietary TPUs, defying earlier market skepticism.GOOGL's vertical integration—owning the model, hardware, and distribution—positions it to reduce reliance on Nvidia and improve AI monetization.A new price target of $345 is set, justified by visible technological advantage, end-to-end AI integration, and strong user engagement.GOOGL risks include regulatory scrutiny and heavy capex, but GOOGL's scale, ecosystem, and cost efficiencies support a continued bullish stance. Sean Gallup/Getty Images News

Thesis There's no doubt that Nvidia (NVDA) is and remains the world's leading manufacturer of chips for video cards (GPUs). The company holds around 90% of the market. For every single chip sold, the margins are enormous; furthermore, integration with CUDA

Analyst’s Disclosure:I/we have a beneficial long position in the shares of GOOGL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Lockheed Martin and RTX show contrasting momentum as fresh contracts, earnings shifts and rising defense demand highlight differing strengths.

Operator

Good morning, and welcome to the EMERGE Commerce's Third Quarter 2025 Results Conference Call. [Operator Instructions] This call is being recorded on November 26, 2025.

Your hosts today are Ghassan Halazon, Founder and Chief Executive Officer; and Dasha Enenko, Chief Financial Officer.

Before we begin, I'm required to provide the following statement respecting forward-looking information, which is made on behalf of EMERGE and all of its representatives on this call.

Certain statements made on this call will contain forward-looking information. These forward-looking statements generally can be identified by the use of words such as intend, believe, could, expect, estimate, forecast, may and other words of similar meaning. This forward-looking information is based on our opinions, estimates and assumptions in light of our experience and perception of historical trends, current conditions and expected future developments as well as other factors that we currently believe are appropriate and reasonable in the circumstances.

Actual results could differ materially from a conclusion, forecast, expectation, belief or projection in the forward-looking information. Certain material factors and assumptions were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information. We caution investors not to rely on the forward-looking information. Additional information about the material factors that could cause actual results to differ materially from the conclusion, forecast or projection in the forward-looking information and material factors or assumptions that were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information, are contained in EMERGE's filings with the Canadian provincial securities regulators.

During

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Key Takeaways Weekly Jobless Claims, Durable Goods Worth Giving Thanks ForDeere Posts Mixed Results in Fiscal Q4Holiday Travel Estimated to Reach New High
Wednesday, November 26, 2025

Pre-market futures are in the green again this hour and holding steady through the release of a few key pieces of data this morning. This follows a highly successful trading day, up half a point to +2%, depending on the market index, on Tuesday. The Dow is +77 points at this hour, the S&P 500 +18 and the Nasdaq +107 points. The small-cap Russell 2000 — that gainer of +2% yesterday — is trading flat at present.

Interestingly, upon the economic reports out ahead of today’s open, the bond market seems to have frozen in place at this hour: +4.01% on the 10-year yield and +3.48% on the 2-year. These bond rates are about as honest a proxy on interest rate sentiment as we currently have, particularly with Fed members now in a “blackout period” regarding the press ahead of the December 10th FOMC decision.

Weekly Jobless Claims Remain Tame: +216K, +1.96M
Thankfully, Weekly Jobless Claims have returned to our weekly discourse on economic analysis; over time, the feeling of “flying blind” without out it had begun to grow somewhat concerning. The good thing is, not much has changed on these metrics, so we don’t feel we’ve missed much over a dormant month and a half.

Initial Jobless Claims came in below estimates — +216K versus expectations for +225K, and below the slightly upwardly revised +222K from the previous week. Aside from an early September +264K anomaly which stand out on the graph like a middle finger, new jobless claims have remained resilient within a +220K-235K range going all the way back to February. In fact, today’s tally comes in below that range; is the jobs market actually improving?

Continuing Claims are even more fascinating in how they’ve stayed in place for so long: today’s total of 1.960 million is actually up from the drastically downwardly revised 1.953 million from the prior week; it originally had come in at 1.974 million a week ago, which was the highest level in four years. Now it’s been revised back into the pack.

From mid-2022 lows on longer-term jobless claims, it took basically a year to move from 1.35 million to 1.8 million. It was nearly two years after that we first saw a 1.9 million tally, which first appeared in May of this year. Over these past six months, we remain below 2 million longer-term jobless claims. You could scarcely wish for jobless rates this calm.

Durable Goods Orders In-Line: +0.5%
Coming off a strangely hot previous month, the delayed September preliminary Durable Goods Orders report came in at +0.5%, as expected. August’s +2.9% was the highest single-month rate in more than a decade. These figures tend to fluctuate depending on the type of durable goods being ordered, which is why this data gets parsed more finely:

Ex-Transportation in general, this bumps up slightly to +0.6% — a similar dynamic to what we saw in Retail Sales reported yesterday — and ramps way up to +0.9% on non-Defense, ex-aircraft durable goods orders (a proxy for “regular” business spending). This is the second month in a row at that +0.9% level, which may point to the hardware buildout in overall AI infrastructure development (this report does not yet segment AI-related businesses).

Taken in combination with the tame jobless claims data, what we can see emerging on the horizon is a familiar “good news is bad news” take: if the labor force remains stout (and jobless claims data does tend to bring better news than monthly job gains reports) and economic spending continues, regardless whether inflation rates are at optimum levels or not, then why in the world would the Fed be interested in lowering interest rates?

Deere & Co. Mixed in Fiscal Q4Machinery giant Deere & Co. (DE - Free Report) is out with fiscal Q4 results ahead of the open, missing earnings estimates by 3 cents to $3.93 per share — the company’s first earnings miss in three years. However, revenues in the quarter came in +5.92% ahead of expectations to $10.58 billion. With a slightly dimmer outlook, shares are trading down -3.5% at this hour, taking a bite out of the stock’s +17.6% gains year to date. For more on DE’s earnings, click here. https://www.zacks.com/stock/news/2795724/deere-de-q4-earnings-miss-estimates
 

Holiday Travel Expected to Reach New Record High
An estimated 31 million people are expected to travel for their Thanksgiving holiday feasts, starting earlier this week. This isn’t necessarily to say that the major airlines -- Delta (DAL - Free Report) , American (AAL - Free Report) and United (UAL - Free Report) , to name but a few -- are seeing a big boost in early trading today (nor have they been much to write home about all year), but it again points to a consumer not shying away from the expenses of travel in late 2025.

If you are traveling to spend time with family and friends, we wish you a happy, safe and healthy weekend. Ahead of Wall Street will return Friday morning for a half-day session in the markets and the ushering-in of Black Friday.

Questions or comments about this article and/or author? Click here>>

Key Takeaways PFE grows oncology and non-COVID revenues, while also trying to expand its pipeline through acquisitions.ABBV drives strong growth from Skyrizi and Rinvoq while expanding oncology and neuroscience sales.PFE faces COVID softness and upcoming LOEs, while ABBV projects steady growth with no major LOEs.
Pfizer (PFE - Free Report) and AbbVie (ABBV - Free Report) are both U.S. pharmaceutical giants with a strong leadership position in various therapeutic areas. For Pfizer, oncology sales comprise around 28% of its total revenues. Outside of oncology, Pfizer has a solid presence in inflammation and immunology, rare diseases and vaccines.

AbbVie has a strong presence in immunology, oncology and neuroscience areas. Other than that, AbbVie also has products for aesthetics and eye care. Its immunology drugs, Skyrizi and Rinvoq, have successfully helped it overcome the loss of exclusivity (LOE) of its blockbuster drug Humira. Immunology accounts for around 50% of AbbVie’s net revenues.

Both companies have promising R&D pipelines capable of delivering innovative treatments and supporting future growth. But which stock presents a better investment opportunity right now? Let’s dive into their fundamentals, growth outlook and potential challenges to make a well-informed comparison.

The Case for PFEPfizer is one of the largest and most successful drugmakers in oncology. The addition of Seagen in 2023 strengthened its position in oncology. Its oncology revenues have risen 7% year to date, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev.

Pfizer’s non-COVID operational revenues are improving, driven by its key in-line products like Vyndaqel, Padcev and Eliquis, new launches and newly acquired products like Nurtec and those from Seagen. Pfizer's recently launched and acquired products rose approximately 9% operationally in the nine months of 2025, with the momentum expected to continue.

Continued growth of Pfizer’s diversified portfolio of drugs, particularly oncology, should support top-line growth in 2026.

Its significant cost reduction and efforts to improve R&D productivity measures are also driving profit growth. Pfizer expects cost cuts and internal restructuring to deliver savings of $7.7 billion by the end of 2027. Pfizer’s dividend yield stands at around 7%, which is impressive.

Pfizer’s new products/late-stage pipeline candidates and newly acquired products position it strongly for operational growth in 2025 and beyond. Pfizer expects the 2025 to 2030 revenue CAGR to be approximately 6%.

Pfizer is also trying to expand its pipeline through acquisitions. It recently won a bidding war against Danish rival, Novo Nordisk (NVO - Free Report) , related to the acquisition of obesity drug developer, Metsera. After a heated battle, with PFE and NVO raising their offer prices for Metsera back and forth, Pfizer eventually acquired Metsera, a New York-based biotech, for around $10 billion. The deal was closed in mid-November. The Metsera acquisition has brought Pfizer back into the lucrative obesity space after it scrapped the development of danuglipron, a weight-loss pill, earlier this year. The acquisition will add Metsera’s four novel clinical-stage incretin and amylin programs, which are expected to generate billions of dollars in peak sales. NVO and Eli Lilly (LLY - Free Report) presently dominate the obesity space.

Pfizer signed a drug pricing agreement with the Trump administration in September. It has offered to cut prescription drug prices and boost domestic investments in exchange for a three-year exemption from tariffs on pharmaceutical imports.

However, Pfizer faces its share of challenges. It is seeing a softness in sales of its COVID products, Comirnaty and Paxlovid, due to lower vaccination rates and COVID infection rates.

Pfizer also expects a significant impact from the loss of patent exclusivity in the 2026-2030 period, as several of its key products, including Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi, will face patent expirations. Pfizer expects an unfavorable impact of approximately $1 billion from the Medicare Part D redesign under the Inflation Reduction Act (IRA), which took effect in the first quarter of 2025 and is hurting Pfizer’s revenues. Higher-priced drugs, including Eliquis, Vyndaqel, Ibrance, Xtandi and Xeljanz, are expected to be most affected by the IRA.

The Case for AbbVieAbbVie has successfully navigated the LOE of Humira, which once generated more than 50% of its total revenues. It has accomplished this by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications, and should support top-line growth in the next few years.

Skyrizi and Rinvoq generated combined sales of $18.5 billion in the first nine months of 2025. Skyrizi sales are now annualizing at almost $18 billion and Rinvoq at more than $8 billion. AbbVie expects to outperform its target of combined sales of Skyrizi and Rinvoq of more than $25 billion in 2025 and more than $31 billion by 2027. AbbVie recently settled patent litigation with all generic manufacturers for Rinvoq, which extended the drug’s patent exclusivity by four years to 2037.

AbbVie’s oncology and neuroscience drugs are also contributing to top-line growth. AbbVie’s oncology segment generated combined revenues of $5.0 billion in the first nine months of 2025, up 2.7% year over year as higher sales of Venclexta and contributions from new drugs, Elahere and Epkinly, more than offset the decline in Imbruvica sales. Sales of its neuroscience drugs increased 20.3% to almost $7.8 billion in the first nine months of 2025, driven by higher sales of Botox Therapeutic, depression drug Vraylar and newer migraine drugs, Ubrelvy and Qulipta.

AbbVie has been on an inorganic growth track over the past couple of years to bolster its early-stage pipeline, which should drive long-term growth. Particularly, it is signing several M&A deals in the immunology space, its core area, while also entering into some early-stage alliances in oncology and neuroscience. AbbVie has executed more than 30 M&A transactions since the beginning of 2024

However, the company faces some near-term headwinds like Humira’s biosimilar erosion, increasing competitive pressure on cancer drug Imbruvica and decreasing sales of the Aesthetics unit. AbbVie’s global sales of its aesthetics portfolio declined 7.4% in the first nine months of 2025.

Continued macro challenges and low consumer sentiment, especially in the United States, with concerns about the economy and inflation weighing on discretionary spending, are hurting aesthetics sales.

How Do Estimates Compare for PFE & ABBV?The Zacks Consensus Estimate for Pfizer’s 2025 sales and EPS implies a year-over-year decrease of 1.1% and an increase of 1%, respectively. The Zacks Consensus Estimate for earnings has risen from $3.07 per share to $3.14 per share for 2025, while that for 2026 has decreased from $3.15 per share to $3.14 per share over the past 30 days.

PFE Estimate MovementImage Source: Zacks Investment Research

The Zacks Consensus Estimate for AbbVie’s 2025 sales and EPS implies a year-over-year increase of 8.1% and 5.1%, respectively. The Zacks Consensus Estimate for 2025 earnings has declined from $10.81 per share to $10.64, while that for 2026 has decreased from $14.41 to $14.40 per share over the past 30 days.

ABBV Estimate MovementImage Source: Zacks Investment Research

Price Performance and Valuation of PFE & ABBVYear to date, while PFE’s stock has declined 3.0%, AbbVie’s stock has risen 30.5%. The industry has risen 15.9% in the said time frame.

Image Source: Zacks Investment Research

Pfizer looks more attractive than AbbVie from a valuation standpoint. Going by the price/earnings ratio, AbbVie’s shares currently trade at 16.52 forward earnings, lower than 16.98 for the industry. However, ABBV currently trades higher than its 5-year mean of 13.40. Pfizer’s shares currently trade at 8.20 forward earnings, lower than the industry. PFE also trades below the stock’s 5-year mean of 10.46

Image Source: Zacks Investment Research

AbbVie’s dividend yield is 2.8%, while Pfizer’s is 6.7%.

Image Source: Zacks Investment Research

PFE or ABBV: Which is a Better Pick?AbbVie and Pfizer have a Zacks Rank #3 (Hold) each, which makes choosing one stock a difficult task. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

However, Pfizer’s upcoming LOE cliff is a major factor that tilts us in favor of AbbVie, as it has faced Humira’s patent cliff quite well and looks well-positioned for continued strong growth in the years ahead. AbbVie is returning to robust revenue growth in 2025, which is just the second year following the U.S. Humira LOE, driven by its ex-Humira platform.

Boosted by its new product launches, AbbVie expects to return to mid-single-digit revenue growth in 2025 with a high single-digit CAGR through 2029, as it has no significant LOE events for the rest of this decade. A substantial portion of this growth is expected to be driven by the robust performance of Skyrizi and Rinvoq. With no significant LOEs in this decade, AbbVie enjoys the flexibility to invest more in R&D to continue to acquire external innovation. Investors looking for companies showing steady growth and margins should choose ABBV stock over PFE.

Key Takeaways JPMorgan, Bank of America and Goldman Sachs are set for rising fixed-income trading revenues ahead.Divergent global rate moves are driving portfolio rebalancing and higher trading activity.A rising fiscal deficit and steepening yield curve are boosting bond and derivatives trading.
The interest-rate markets have been witnessing a surge in trading activities since the beginning of this year, with opportunities expected to continue into 2026. Several macro forces like interest-rate adjustments by global central banks, tariff uncertainty, mounting fiscal deficit concerns and a sharp steepening of the yield curve are expected to create more trading opportunities in the near term, thus helping fixed income traders earn more fees.

Wall Street banks like JPMorgan (JPM - Free Report) , Bank of America Corporation (BAC - Free Report) and The Goldman Sachs Group, Inc. (GS - Free Report) are likely to see a continued rise in fixed-income trading revenues in the quarters ahead.

In the nine months ended Sept. 30, 2025, JPMorgan’s fixed-income markets revenues in the Commercial & Investment Bank (CIB) segment increased 14% year over year to $17.2 billion. Bank of America reported a 9.6% year-over-year increase in its fixed-income, currencies and commodities (FICC) trading revenues within the Global Markets segment.

Likewise, for Goldman Sachs, its FICC revenues increased 8% on a year-over-year basis.

How Will Banks Benefit From Divergent Rate Policies?Global central banks have been moving interest rates in different directions. For instance, while the U.S Federal Reserve and European Central Bank have been cutting rates this year, the Bank of Japan has initiated a move to raise rates.

Because of this divergence, investors are forced to rebalance their portfolios because bonds become more attractive in a country that is reducing interest rates and vice versa. As investors buy and sell rates products, credit instruments and commodities to adjust to the new monetary-policy landscape, this rebalancing creates volatility in the markets, leading to a rise in trading activities.

And, as fixed income trading activities increase, major dealers with rates trading desks, including Goldman Sachs, JPMorgan and BofA, will benefit.

How Will Rising Fiscal Deficit & Steepening Yield Curve Aid Trading?In situations of rising fiscal deficits, governments need to borrow more money, which they do by issuing bonds. When more bonds are issued, there are more bonds available to buy and sell. This means that there will be an increase in trading volumes around those bonds.

Similarly, when long-term interest rates increase more quickly than short-term rates, the yield curve steepens, which triggers three types of trading behavior, like hedging, speculation or repositioning. All these activities involve a lot of buying and selling of bonds and derivatives.

Currently, JPM and Goldman Sachs carry a Zacks Rank #3 (Hold) while Bank of America has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Takeaways PRIM delivers steady EPS growth and strong project demand, but margin pressures and project delays hurt.MTZ shows sharper growth catalysts, record backlog and a pipeline rebound, though at a premium valuation.EPS trajectories favor MTZ's high-octane recovery, while PRIM appeals to investors seeking moderated growth.
The robust public infrastructure spending environment is benefiting firms operating in the infrastructure and specialty-construction markets focused on utilities, energy, pipeline and heavy civil projects. Companies like Primoris Services Corporation (PRIM - Free Report) and MasTec, Inc. (MTZ - Free Report) are a few names that are leveraging the incremental market trends.

Besides a favorable funding scenario, the two back-to-back Fed rate cuts are acting as a catalyst in boosting prospects further. After a 0.25 percentage point rate cut on Sept. 17, 2025, the Federal Reserve again pulled down the interest rate by another 25 basis points on Oct. 29, moving the targeted benchmark between 3.75% and 4.00%. With another expected rate cut in December 2025 and two more by June 2026 (per Goldman Sachs chief economist Jan Hatzius), the growth optimism surrounding the economy is in favor of the companies mentioned above.

Primoris Services is currently focused on executing cost control initiatives and disciplined capital management amid the favorable market fundamentals. Contrarily, MasTec is considering further boosting the growth prospects witnessed across its Pipeline Infrastructure segment, alongside maintaining meaningful growth in its non-pipeline businesses.

Let’s dive deep and closely compare the fundamentals of the two stocks to determine which one is a better investment now.

The Case for Primoris Services StockThis Texas-based specialty construction and infrastructure company is gaining from solid project execution strategies amid healthy end-market demand, accompanied by its cost control efforts and disciplined capital management. PRIM has been witnessing robust demand trends across the power delivery, gas operations, communications, renewable energy and industrial markets.

Moreover, the passing of the One Big Beautiful Bill Act is a cherry on the cake. This act highlights tax incentives like bonus depreciation across infrastructure investments and allocates about $150 billion of mandatory defense spending. This strategic move is in favor of Primoris Services as it has enabled its customers to have a substantial volume of projects lined up for the next few years.

Primoris Services’ internal execution remains encouraging despite a challenging macro environment and supportive public spending. Adjusted EPS for the first nine months of 2025 rose 65.7% year over year to $4.54, driven by revenue growth, lower interest expense and reduced SG&A. Confident in its diversified markets and solid fundamentals, the company raised its 2025 adjusted EPS outlook to $5.35-$5.55, up from $4.90-$5.10 and well above the 2024 figure of $3.87.

However, PRIM continues to face margin pressures across both operating segments, raising concerns about its ability to sustain profitability despite cost controls and efficiency efforts. Third-quarter 2025 margins contracted 120 basis points to 10.8%, reflecting lower higher-margin storm work, fewer favorable impacts from renewables and industrial projects compared with 2024 and increased costs on certain renewables projects due to adverse weather and project delays.

The Case for MasTec StockThis Florida-based infrastructure construction company is benefiting from strong activity across communications, clean energy and power delivery markets. Besides, a record backlog highlighted persistent demand tied to energy transition and infrastructure investment. As of Sept. 30, 2025, the company’s 18-month backlog stood at a record level of $16.78 billion, up 21.1% year over year and 2% sequentially. MasTec offers services for renewables projects through its Clean Energy and Infrastructure segment, whose 18-month backlog grew 21.4% year over year on strong renewables demand, mainly solar.

After going through a rough patch since the start of 2025, MasTec’s Pipeline Infrastructure segment’s revenues grew 20% year over year to $597.8 million, with EBITDA margin showing sequential growth of 390 basis points to 15.4%. Increasing multi-year spending across grid reliability, LNG expansion and energy transition infrastructure is driving the momentum. Also, MTZ’s improved bidding discipline, a more favorable mix of midstream projects, better project execution and healthier backlog conversion are boding well amid favorable government funding initiatives.

Despite thriving in the energy and power markets, MasTec is facing several challenges that are impacting its revenue visibility and margin growth. It has been experiencing performance setbacks due to fluctuations in capital spending, alongside being continuously subject to project delays.

During the third quarter of 2025, MTZ toned down the 2025 revenue guidance for its Power Delivery segment to about $4.075 billion from the prior expected range of $4.225-$4.25 billion. This move was undertaken because of a lower level of activity related to its Greenlink project, as the customer is facing isolated delays due to permitting.

Stock Performance & ValuationAs witnessed from the chart below, in the past three months, MasTec’s share price performance has outperformed Primoris Services’ growth and the broader Construction sector.

Image Source: Zacks Investment Research

Considering valuation, over the last five years, MasTec has been trading above Primoris Services on a forward 12-month price-to-earnings (P/E) ratio basis.

Image Source: Zacks Investment Research

Overall, from these technical indicators, it can be deduced that MTZ stock offers an incremental growth trend but with a premium valuation, while PRIM stock offers a diminishing growth trend with a discounted valuation.

Comparing EPS Estimate Trends: PRIM vs. MTZThe Zacks Consensus Estimate for PRIM’s 2025 EPS indicates 31.3% year-over-year growth, with the 2026 estimate indicating an improvement of 9.3%. The 2025 and 2026 EPS estimates have remained stable over the past 60 days.

PRIM's EPS Trend

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for MTZ’s 2025 earnings implies a year-over-year rise of 60.8%, while the same for 2026 indicates an uptick of 27%. Its 2025 and 2026 EPS estimates have trended upward over the past 30 days by 0.5% and 3.6%, respectively.

MTZ's EPS Trend

Image Source: Zacks Investment Research

Which Stock to Pick Now: PRIM or MTZ?Primoris Services is executing well across diversified end markets, aided by cost controls and strong demand in power delivery, gas operations, communications and renewables. However, persistent margin pressure remains a key concern, due to reduced high-margin storm work, weaker renewables contributions and rising costs tied to weather-related delays.

On the other hand, MasTec is capitalizing on record backlog strength and broad momentum across communications, power delivery and clean energy. But the company continues to grapple with project delays, fluctuating customer capital spending and trimmed guidance for its Power Delivery segment due to permitting setbacks.

Although MTZ stock is trading at a premium, its growth trajectory appears stronger and consensus estimates are rising compared with PRIM stock, which is at a discounted valuation. Although both stocks are currently carrying a Zacks Rank #3 (Hold), MTZ holds a robust near-term edge on execution momentum and backlog strength, making it a comparatively better investment option over PRIM now. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Takeaways OPFI posted Q3 revenues of $155.1M with strong originations and sharply lower net charge-offs.OppFi raised its 2025 revenues and adjusted EPS guidance, signaling improving demand and execution.NU added 4.3M customers and delivered higher margins, stronger asset quality and robust loan growth.
Both OppFi Inc. (OPFI - Free Report) and Nu Holdings Ltd. (NU - Free Report) are fintech companies that specialize in consumer lending for the underserved population and emerging credit markets.

We have analyzed both stocks to determine which offers the most upside.

The Case for OppFiOPFI experienced a strong third quarter of 2025, marked by top-line growth and profitable expansion in its core operations. With $155.1 million in revenues, OppFi registered 13.5% year-over-year growth. Multiple factors directed this top-line trajectory, including a 12.5% year-over-year hike in net originations. Increasing customer demand was met with an elevated auto approval rate that increased to 79% from the year-ago quarter. Furthermore, the top-line growth can be partly attributed to the consistent rise in scalability in partnerships and direct response programs.

During the said quarter, adjusted net income improved 41.4% year over year to $40.7 million. A combination of strong revenue growth and disciplined expense management enabled the company to acquire this level of profitability. This lofty growth led the bottom line to surge by 39.1% year over year. OppFi’s Model 6, standing at the apex of its credit mitigation strategy, continued to perform well, as evidenced by the net charge-off as a percentage of total revenues taking a nose dive of 430 bps and the net charge-off as a percentage of average receivables falling 480 bps during the nine months ended Sept. 30, 2025.

Management raising 2025 guidance for the top and bottom line again is a waving green flag. During the first quarter of 2025, revenues for the full year were expected to hover within $563-$594 million, which was revised to $590-$605 million during the recently reported quarter. On a similar note, during the third quarter of 2025, adjusted EPS was expected to $1.54-$1.6, which is a significant jump from the first quarter’s $1.18-$1.26. This highlights an anticipation of high demand and operational enhancement boding well with investors.

The Case for Nu HoldingsNu Holdings displayed a robust third quarter of 2025 performance, with revenues gaining 39% year over year, banking on surging customer demand. The company added 4.3 million new customers during the quarter, increasing the count by 16% year over year. As of September 2025, NU’s customer count in Brazil, Mexico and Colombia stood at 110.1 million, 13.1 million, and 3.8 million, respectively, representing 60%, 14% and 10% of the adult population in these regions. It indicates that the company is a leading digital bank in Latin America and one of the leading fintech platforms globally.

On the profitability front, NU witnessed significant improvement as evidenced by its gross profit of $1.8 billion, increasing 32% year over year. The expansion of its margin to 43.5% highlights consistent revenue growth accompanied by consistent improvement in risk-adjusted performance. The company registered net income of $783 million, up a whopping 41.6% year over year. Management stated that such strong profitability is a result of its business model, which is appealing to the masses and fosters strong engagement that broadens monetization. It is striking how all of this is possible while operating on a low-cost and efficient platform.

Nu Holdings’ strategy to diversify both deposits and credit was successful, with deposits growing 37.1% year over year to $38.8 billion, and the loan portfolio witnessing a 42% year-over-year increase to $30.4 billion. Asset quality improved as evidenced by a 20-basis point decline in the 15 to 90-day Non-Performing Loan ratio from the year-ago quarter, despite sector seasonality. NU’s tech investments are targeted toward AI-backed risk and engagement initiatives to aid long-term productivity. Nu Holdings’ swift scale, geographic leadership, and recurring revenues paint a compelling picture of gains in the long haul.

How Do Estimates Compare for OPFI & NU?The Zacks Consensus Estimate for OPFI’s 2025 sales and EPS shows year-over-year growth of 13.6% and 65.3%, respectively. Two estimates for 2025 have increased over the past 60 days, with no downward revisions.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for NU’s 2025 sales and EPS indicates a year-over-year increase of 35.9% and 31.1%, respectively. Two estimates for 2025 have moved north in the past 60 days, with no southward revision.

Image Source: Zacks Investment Research

OPFI Trades Cheaper Than NUOppFi is trading at a forward earnings multiple of 5.68 times, lower than its 12-month median of 6.91 times. Nu Holdings’ forward earnings multiple stands at 20.76 times, slightly higher than its median of 20.71. OPFI trades significantly cheaper than NU.

Image Source: Zacks Investment Research

VerdictOPFI managed to cater to the piling customer demand, leveraging its Model 6. The company’s credit risk mitigation tactics presented positive results as evidenced by the fall in the net charge-off as a percentage of total revenues. Furthermore, management’s heightened expectations of the top and bottom line for the full year have a strong appeal among investors.

NU’s ability to draw in more customers positions it well as a leading digital bank in Latin America. Nu Holdings’ business model, which operates a low-cost platform, deepens customer engagement and expands monetization. Furthermore, the company’s improving asset quality, combined with investments in AI, adds to its long-term growth trajectory.

Both companies are compelling fintech players; however, we consider OPFI to offer a better upside on the grounds that it is trading at a discount compared with NU. OppFi’s underpriced valuation makes it particularly appealing to value investors.

OPFI flaunts a Zacks Rank #1 (Strong Buy) while NU carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

XOM's integrated strength and low-cost assets contrast with COP's upstream focus as investors weigh stability versus risk.

BTC price remains under the $90K resistance zone — a barrier it just can’t break thanks to ETF outflows and a bearish market backdrop.

With that in mind, traders are asking: what’s the BTC outlook in the short term, and is this bounce real or just temporary?

Summary

Bitcoin is trading near $86.6K, around 30% below its October peak of $126.2K, with recent volatility reflecting broader market trends and $3.5B in November ETF outflows.
Spot Bitcoin ETFs saw $238M in inflows after a month of outflows, potentially helping stabilize the market.
A move above $88K could trigger a retest of the $90K resistance, while continued ETF inflows may support a potential further push.
Downside Risks: Failure to break $90K and a drop below $85K could lead BTC toward $80K, confirming the ongoing bear-cycle correction.
BTC is expected to consolidate between $85K–$90K with high volatility, while holding the $80K–$85K support zone is crucial to avoid prolonged weakness.

Current price scenario
Bitcoin (BTC) is trading near $86.6K, about 31.3% below its $126.2K peak from October. The recent volatility fits the broader market trend, particularly as November saw $3.5B in ETF outflows, signaling that institutional investors are taking a step back.

BTC 1-day chart, November 2025 | Source: crypto.news
But things aren’t entirely negative: spot Bitcoin ETFs just saw $238M in inflows after a month of outflows. If that continues, it could steady the market. 

Zooming out, the drop fits the typical 4-year cycle pattern, placing Bitcoin in its usual post-peak corrective phase.

Upside outlook
Even though the market is weak right now, the upside remains clear. A move above $88,000 would shift short-term momentum toward buyers, possibly triggering a retest of the important $90,000 resistance. That level has repeatedly acted as both a technical and psychological ceiling for BTC.

Continued ETF inflows could provide the fuel needed to sustain an upward move.

Downside risks
Risks to the downside remain high for Bitcoin. The $90,000 resistance has repeatedly blocked upward momentum, and if it continues to hold, BTC may face another corrective leg.

Immediate support comes at $85,000. A breakdown below this level could accelerate selling and push Bitcoin toward the $80,000 support zone. Entering the $80K range would likely confirm that the bear-cycle correction is still in effect, putting near-term sentiment under pressure and delaying any sustained recovery.

Bitcoin price prediction based on current levels
With technical resistance, ETF trends, and the cyclical backdrop in mind, the short-term BTC forecast is neutral but watchful. Bitcoin is likely to trade between $85K and $90K as market participants jockey for control. A clean move above $90K would be a key sign of bullish momentum, while a fall below $85K could trigger more corrective pressure.

All told, the short-term Bitcoin price prediction points to continued consolidation and high volatility. Medium-term developments will hinge on ETF inflows and macro conditions, and holding the $80K–$85K support zone will be key to avoiding an extended period of weakness.

Disclosure: This article does not represent investment advice. The content and materials featured on this page are for educational purposes only.

Bitcoin (BTC) hovered near $87,000 at the Wednesday Wall Street open as analysts eyed short liquidations.

Key points:

Bitcoin liquidity conditions analysis predicts a return toward $90,000 next.

Range-bound short-term price moves see trader bets pile in either direction.

US macro data gives stocks a modest boost but fails to sway crypto.

Liquidity could see BTC “pulled up” toward $89,000Data from Cointelegraph Markets Pro and TradingView showed flat BTC price action characterizing the day’s trading.

BTC/USD one-hour chart. Source: Cointelegraph/TradingView
A lack of volatility allowed liquidity to build either side of price, with $88,000 now an area of interest for trading resource TheKingfisher.

“There are a lot of short liquidations for $BTC on Binance around $88,253.90, which means the price could get pulled up towards that level,” it explained in a post on X.

BTC order-book liquidity data. Source: TheKingfisher/X
Crypto investor and entrepreneur Ted Pillows flagged $89,000 as the key reclaim level for shorts to feel the pain.

“If BTC reclaims the $89,000 level, upside liquidity will be swept first. If Bitcoin loses the $85,000 level, the downside liquidity will be taken out before a bounce back,” he told X followers the day prior.

Data from monitoring resource CoinGlass put the major liquidity draws at $84,500 and $88,500 at the time of writing.

BTC liquidation heatmap. Source: CoinGlass
Crypto analyst Lennaert Snyder noted that the long/short ratio among traders was “roughly 50/50” into $89,000 resistance.

“We need Bitcoin to eat some stop losses and grab fuel before the next directional move,” he commented. 

“Two scenario's I like is either we gain $89K, or sweep the $80.6K lows and bounce back.”Bitcoin steady as S&P 500 heads higherThe day’s macroeconomic data prints had little impact on the stubborn BTC price action.

US jobless claims came in below expectations, potentially reflecting strengthening labor-market conditions.

Despite this, stocks climbed after the open, while bets of a Federal Reserve interest-rate cut in December remained favorable to risk assets.

CME Group’s FedWatch Tool put the odds of a 0.25% cut at the Fed’s Dec. 10 meeting at 83% at the time of writing — up considerably from 30% just a week prior.

Fed target rate probability comparison (screenshot). Source: CME Group
While acknowledging rising fear levels, trading resource The Kobeissi Letter stressed that the S&P 500 was now just 2% away from fresh all-time highs.

“Asset owners are winning,” it concluded.

Investor fear levels are rising:

The cost of a 5-year put option protecting against at least a -55% drop in the S&P 500 has risen to 46 basis points, the highest since the April sell-off.

Excluding April, this is the highest level in at least 2 years.

This means investors are… pic.twitter.com/5SEXCSpfjy

— The Kobeissi Letter (@KobeissiLetter) November 26, 2025This article does not contain investment advice or recommendations. Every investment and trading move involves risk, and readers should conduct their own research when making a decision.